X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

UPS Healthcare Accelerates Cold Chain Capabilities

Content Team by Content Team
7th June 2021
in Packaging & Logistic, Press Statements
UPS Healthcare Accelerates Cold Chain Capabilities

UPS is expanding its specialty pharmaceutical offerings by establishing UPS Cold Chain Solutions, a comprehensive suite of cold chain technologies, best-in-class capabilities, and new and expanded global facilities providing complete, end-to-end temperature-controlled logistics.

“Our customers have been taking advantage of our cold chain capabilities for years, but the pandemic caused UPS to move even faster to enhance an integrated set of cold chain solutions to support the future of the pharmaceutical and medical device industry,” said Wes Wheeler, UPS Healthcare president. “UPS’s near-perfect, on-time delivery of the COVID-19 vaccine proves how effectively and efficiently our network handles biologically derived drugs, even at extreme temperatures.”

Chronic and life-threatening diseases, including cancers, respiratory, autoimmune and cardiovascular conditions, are the fastest growing disease categories in the world, creating a rapid acceleration in the development of biologically derived, temperature-controlled drugs and therapies. According to the, cold chain trends show 48 percent growth between 2018 and 2024 for drugs that require at least 2 to 8 degrees Celsius storage and shipping. Additionally, the overall market for cold chain services (packaging, transportation and data services) is expected to significantly accelerate growth over the next three years, growing by 24 percent by 2024, after posting a 10 percent increase from 2019 to 2020.

“The future of the healthcare and specialty pharmaceutical industries will increasingly rely on robust cold chain networks to safely deliver temperature-controlled drugs and therapies to customers,” said Kate Gutmann, UPS chief sales and solutions officer and SVP, UPS Global Healthcare. “The continued evolution of our cold chain offerings ensures UPS is ready for the future and can continue to provide long-term value for our healthcare customers.”

Managing temperature excursion end-to-end

UPS Cold Chain Solutions is purpose-built to provide pharmaceutical companies, healthcare providers and laboratories a full, end-to-end cold chain service offering, including storage and distribution, transportation, visibility, and quality assurance capabilities to meet their complex demands for critical products around the world.

As part of a continued, aggressive strategy to build sophisticated capabilities in cold chain logistics, UPS Healthcare is expanding and augmenting its temperature-controlled products and services, including:

  • Cold chain GMP storage capacities – roughly 390,000 square feet of coolers and freezers installed at UPS facilities to support the storage of biologics ranging from 2 degrees Celsius to as low as minus-80 degrees Celsius
  • Packaging customization – recommendations for specific temperature-controlled packaging options to minimize total cost while ensuring safe and efficient transportation of products
  • UPS European cold chain ground network expansion – adding more ground transportation fleets, better connection between gateways and teams of experts to create customizable solutions that fit our customers’ needs
  • Transportation efficiencies – four flexible, temperature-regulated service options via air or ocean freight that can be configured to meet the needs of the pharmaceutical packaging and help keep customer costs down
  • Precise monitoring with UPS® Premier technology – protocols to provide pinpoint visibility into covered pallets, boxes, trailers and packages within 10 feet of their location anywhere in the UPS network
  • Facility updates – construction of two new GDP-compliant, healthcare-licensed distribution facilities in Italy and Australia, as well expansions and cold chain retrofit projects to facilities in The Netherlands, Czechia, Poland, Hungary and the U.S.

“UPS sets a high bar for excellence in cold chain delivery and logistics, and these current and future investments in innovative solutions will ensure we keep pushing the bar higher,” Wheeler said. “For our customers, we will remain focused on delivering on our commitment to ‘Quality Focused. Patient Driven.’”

You can learn more about UPS Cold Chain Solutions and other UPS Healthcare initiatives by visiting: www.ups.com/healthcare.

About UPS Healthcare

UPS Healthcare has 11 million square feet of GMP- and GDP-compliant healthcare distribution space in 128 facilities in 32 countries. UPS Healthcare services include: inventory management, temperature-controlled packaging and shipping, storage and fulfillment of medical devices, labs and clinical trial logistics. UPS Healthcare’s global infrastructure, its newest UPS Premier visibility service, its track and trace technology, and its global quality system are well-suited to meet today’s complex logistics demands for the pharmaceutical, medical device and laboratory diagnostic industries.

Previous Post

UK MHRA approves one-dose Janssen Covid-19 vaccine

Next Post

Vetter Once Again Wins Axia Best Managed Companies Award

Related Posts

ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Drug Development

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

4th March 2025
Drug Development

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

4th March 2025
Next Post
Vetter Once Again Wins Axia Best Managed Companies Award

Vetter Once Again Wins Axia Best Managed Companies Award

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In